Treats X-linked hypophosphatemia (XLH). Sold as Crysvita. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Burosumab-Twza (sold as Crysvita), first approved Apr 17, 2018, with 4 new uses approved and 0 published complete response letters.
| Crysvita | Part D | $75.5M | +35% | 208 |
| Crysvita | Part B | $25.5M | +6% | 86 |
| Effective Dosing of Burosumab in XLHX-linked Hypophosphatemia (XLH) · University of Nottingham | — | Recruiting | Sep 19, 2025 |
| Tumor-induced Osteomalacia Disease Monitoring ProgramTumor-induced Osteomalacia (TIO) · Ultragenyx Pharmaceutical Inc | — | Active, not recruiting | Mar 5, 2021 |
| Burosumab and 1-25 (OH) Vitamin D on Human OsteoblastsCraniosynostoses · Hospices Civils de Lyon | — | Recruiting | Nov 12, 2019 |
| X-linked Hypophosphatemia Disease Monitoring ProgramX-linked Hypophosphatemia, Hypophosphatemic Rickets · Ultragenyx Pharmaceutical Inc | — | Active, not recruiting | Aug 29, 2018 |
| Registry for Patients With X-Linked HypophosphatemiaX-Linked Hypophosphatemia · Kyowa Kirin Pharmaceutical Development Ltd | — | Recruiting | Jun 20, 2017 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 17, 2018 | CrysvitaBLA 761068 · New molecular entity | Kyowa Kirin | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA